NCT05967377View on ClinicalTrials.gov

Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 16, 2018

Primary Completion Date

February 12, 2019

Study Completion Date

February 12, 2019

Conditions
PharmacokineticsBioavailability
Interventions
DRUG

Sorafenib - Period 1

Sorafenib (Nexavar®) Tablet, 200 mg

DRUG

XS005 Sorafenib Capsule A - Period 1

XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)

DRUG

XS005 Sorafenib Tablet A - Period 1

XS005 Sorafenib Tablet A, 100 mg

DRUG

XS005 Sorafenib Capsule A - Period 2

XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)

DRUG

XS005 Sorafenib Tablet A - Period 2

XS005 Sorafenib Tablet A, 100 mg

DRUG

Sorafenib - Period 2

Sorafenib (Nexavar®) Tablet, 200 mg

DRUG

XS005 Sorafenib Tablet A - Period 3

XS005 Sorafenib Tablet A, 100 mg

DRUG

Sorafenib - Period 3

Sorafenib (Nexavar®) Tablet, 200 mg

DRUG

XS005 Sorafenib Capsule A - Period 3

XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)

Trial Locations (1)

NG11 6JS

Quotient Sciences, Nottingham

All Listed Sponsors
lead

Xspray Pharma AB

INDUSTRY

NCT05967377 - Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects | Biotech Hunter | Biotech Hunter